Diffuse Large B-cell Lymphoma Therapeutics Industry Insights: Market Forecast to 2029
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Larger Is The Diffuse Large B-cell Lymphoma Therapeutics Market Expected To Become By 2029 Compared With Its 2025 Level?
The diffuse large b-cell lymphoma therapeutics market has experienced significant growth in recent years. It is anticipated to expand from $4.74 billion in 2024 to $5.1 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The historical increase can be ascribed to advancements in clinical research, successful regulatory approvals, enhanced patient awareness and diagnosis, various collaborative initiatives, and the ongoing development of the standard of care.
The diffuse large b-cell lymphoma therapeutics market is projected to experience substantial growth over the next few years. It is forecast to expand to $6.92 billion by 2029, achieving a compound annual growth rate (CAGR) of 7.9%. This expansion during the forecast period is propelled by factors such as biomarker discovery, advancements in immunotherapy, increasing incidence rates, the global aging population, the development of healthcare infrastructure, and wider access to novel drugs. Key trends anticipated in the forecast period encompass the increasing prevalence of outpatient treatment settings, collaborative clinical trials, patient-centric care models, progress in diagnostic imaging techniques, and the digitalization of healthcare.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10805&type=smp
Which Major Market Drivers Are Shaping The Future Of The Diffuse Large B-cell Lymphoma Therapeutics Market?
The rising incidence of diffuse large B-cell lymphoma (DLBCL) is projected to spur the expansion of the diffuse large B-cell lymphoma therapeutics market moving forward. Diffuse large B-cell lymphoma (DLBCL) constitutes an aggressive form of cancer that originates from B-cells within the lymphatic system, distinguished by its rapid and widespread growth. It falls under the category of non-Hodgkin lymphoma (NHL). The therapeutics designed for diffuse large B-cell lymphoma contribute to better outcomes for individuals already afflicted with the condition by focusing on and controlling the cancer cells. For example, the American Cancer Society, a US-based voluntary health organization, estimated that approximately 80,550 people (44,880 males and 35,670 females) would be diagnosed with non-Hodgkin’s lymphoma (NHL) in 2023, with around 20,180 individuals expected to die from NHL. Therefore, the increasing occurrence of diffuse large B-cell lymphoma (DLBCL) drives the growth of the diffuse large B-cell lymphoma therapeutics market.
How Is The Diffuse Large B-cell Lymphoma Therapeutics Market Segmented?
The diffuse large b-cell lymphoma therapeutics market covered in this report is segmented –
1) By Drug Class: Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs
2) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies
3) By Route of Administration: Oral, Parenteral, Other Routes
4) By End User: Hospitals, Clinics, Other End-Users
Subsegments:
1) By Cisplatin: Injection Formulations, Combination Therapies
2) By Carboplatin: Injection Formulations, Combination Therapies
3) By 5-Fluorouracil: Injection Formulations, Oral Formulations
4) By Docetaxel: Injection Formulations, Combination Therapies
5) By Paclitaxel: Injection Formulations, Combination Therapies
6) By Methotrexate: Injection Formulations, Oral Formulations, Combination Therapies
7) By Other Drugs: Monoclonal Antibodies, Targeted Therapies, Immunotherapies, Experimental Therapies
What Trends Are Expected To Drive The Diffuse Large B-cell Lymphoma Therapeutics Market?
A significant trend gaining traction in the diffuse large B-cell lymphoma therapeutics market involves the development of new drug therapies. Major companies operating within this market are focused on creating therapeutic drugs to sustain their presence. For instance, in June 2022, Bristol-Myers Squibb, a US-based pharmaceutical company dedicated to drug research and development, obtained US FDA approval for its CAR T Cell Therapy Breyanzi. This therapy is approved for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed or refractory large B-cell lymphoma. Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy applicable to a broad spectrum of patients including those with primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B.
Who Are The Key Multinational Companies Dominating The Diffuse Large B-cell Lymphoma Therapeutics Market?
Major companies operating in the diffuse large B-cell lymphoma therapeutics market include Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Xencor Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG
Download The Full Report For Exclusive Market Findings:
Which Global Regions Are Influencing The Competitive Landscape Of The Diffuse Large B-cell Lymphoma Therapeutics Market?
North America was the largest region in the global diffuse large B-cell lymphoma therapeutics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diffuse large B-cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Diffuse Large B-cell Lymphoma Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=10805&type=smp
Browse Through More Reports Similar to the Global Diffuse Large B-cell Lymphoma Therapeutics Market 2025, By The Business Research Company
Testosterone Replacement Therapy Global Market Report 2025
Hormone Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report
Pneumatic Compression Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pneumatic-compression-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
